(VIANEWS) – The NASDAQ ended the session with Zai Lab rising 13.4% to $38.21 on Wednesday, following the last session’s upward trend. NASDAQ jumped 4.41% to $11,468.00, after three successive sessions in a row of losses, on what was a very up trend trading session today.

Zai Lab’s last close was $33.69, 60.08% under its 52-week high of $84.39.

About Zai Lab

Zai Lab Limited is a company that develops and markets therapies for oncology and autoimmune disorders. It also has a focus in neuroscience. Zejula is a once daily small-molecule, poly polymerase 1/2 inhibitor. Optune delivers treatment fields to tumors. NUZYRA treats skin structures and acute bacterial infections. Qinlock can treat gastrointestinal tumors. Odronextamab is also developed to treat diffuse large B cell lymphoma and other types of B-celllymphomas. Repotrectinib (a tyrosinekinase inhibitor) targets ROS1 or TRK A/B/C for patients who have been treated with TKI. Margetuximab can be used to treat breast cancer and stomach cancer. Adagrasib treats KRAS G12C-mutated NSCLC. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited, a Shanghai-based company was established in 2013.

Earnings per Share

Zai Lab’s trailing twelve-month EPS is $-3.46.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a company relative to shareholders’ equity, was negative at -36.66%.


The intraday variation average for Zai Lab in the last week, month, and quarter was 0.377%, 1.83% and 5.39%, respectively.

Zai Lab had the highest average volatility amplitude at 5.30%, 6.00% and 5.39% respectively in the last week.

Sales Growth

The current quarter saw Zai Lab sales grow by 24.6% and 38.6%, respectively.

Annual Top and Bottom Value

At 18:55 EST Zai Lab stock was valued at $38.21, which is way lower than the 52-week high at $84.39 but much higher than the 52-week low at $20.98.


The Zai Lab’s current reported volume is 592437, which is 12.28% lower than its average volume (675404).

More news about Zai Lab (ZLAB).